A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Updates from The Motley Fool

Latest updates on Celgene from Fool.com.  The Fool has written over 800 articles on Celgene.
3 Top Biotech Stocks for 2018

Celgene Corp., Juno Therapeutics, and Cara Therapeutics are three biotech stocks to watch in 2018.

How to Invest in Biotech Stocks

The biotech sector is full of millionaire-maker stocks. But how do you separate the gems from the...

Stop Panicking About Celgene

One quote from management tells you exactly why you shouldn’t believe all the doom and gloom.



Stock Performance

View Interactive CELG Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celgene.
Current Price: $109.00
Prev Close: $108.24
Open: $109.28
Bid: $109.05
Ask: $109.09
Day's Range: $107.68 - $109.64
52wk Range: $94.55 - $147.17
Volume: 3,354,868
Avg Vol 6,290,014
Market Cap: $86B
P/E (ttm): 25.41
EPS (ttm): $4.26
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celgene.
CAPS Rating 5 out of 5
 
2253 Outperform
78 Underperform
CAPS All Stars
 
460 Outperform
11 Underperform

How do you think Celgene will perform against the market?



You pick for Celgene is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark J. Alles, CEO

92% Approve

Based on 47 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celgene.

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers